Table 1. Demographic data and baseline characteristics of all treatment-experienced CHB patients.
| Total(N = 57) | HBeAg-positive(N = 24) | HBeAg-negative(N = 33) | |
|---|---|---|---|
| Male gender | 45 (78.9) | 15 (62.5) | 30 (90.9) |
| Age, years | 40.0 (31.5, 47.0) | 34.0 (30.3, 40.5) | 45.0 (38.5, 50.0) |
| Prior therapy | |||
| IFN | 17 (29.8) | 8 (33.3) | 9 (27.3) |
| NUC | 40 (70.2) | 16 (66.7) | 24 (72.7) |
| Liver cirrhosis | 3 (5.3) | 0 (0) | 3 (9.1) |
| Platelet, 103/uL | 180 (150, 208) | 197 (157, 248) | 174 (145, 197) |
| ALT, U/L | 103.0 (71.5, 163.5) | 112.0 (74.3, 171.3) | 96.0 (66.0, 142.0) |
| ALT | |||
| 1-≤2x ULN | 17 (29.8) | 7 (29.2) | 10 (30.3) |
| 2 - 5x ULN | 35 (61.4) | 14 (58.3) | 21 (63.6) |
| > 5x ULN | 5 (8.8) | 3 (12.5) | 2 (6.1) |
| Albumin, g/dL | 4.2 (4.1, 4.4) | 4.1 (4.0, 4.3) | 4.3 (4.2, 4.4) |
| Total bilirubin, mg/dL | 1.0 (0.8, 1.3) | 0.9 (0.8, 1.2) | 1.0 (0.8, 1.3) |
| Creatinine, mg/dL | 0.9 (0.7, 1.0) | 0.9 (0.7, 0.9) | 1.0 (0.8, 1.0) |
| Prothrombin time (INR) | 1.04 (1.00, 1.12) | 1.04 (1.00, 1.13) | 1.04 (1.00, 1.10) |
| Genotype | |||
| B | 34/55 (61.8) | 12/22 (54.5) | 22 (66.7) |
| C | 21/55 (38.2) | 10/22 (45.5) | 11 (33.3) |
| HBV DNA, log10 IU/mL | 6.6 (5.8, 7.8) | 7.6 (7.1, 8.1) | 6.1 (5.0, 6.8) |
| HBsAg, log10 IU/mL | 3.4 (2.9, 3.9) | 3.8 (3.6, 4.4) | 3.2 (2.3, 3.6) |
Continuous variables: median (25th, 75th percentiles); categorical variables: numbers(percentages)
Missing data: genotype—2
IFN: interferon; NUC: nucleos(t)ide analogue; ALT: alanine aminotransferase; ULN: upper limit of normal; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen